Dexcom, a San Diego-based company behind a line of popular diabetes treatment products, is laying off 535 workers and pulling a slew of manufacturing jobs out of California.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the ...

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights ...